Literature DB >> 24464660

Late and very late onset group B Streptococcus sepsis: one and the same?

Joseph B Cantey1, Courtney Baldridge, Rachel Jamison, Leticia A Shanley.   

Abstract

BACKGROUND: This study aimed to describe the clinical characteristics of group B Streptococcus (GBS) sepsis in infants aged 4-90 days [late onset (LO)] compared to infants >90 days of age [very late onset (VLO)].
METHODS: Microbiology records at Children's Medical Center Dallas were screened. Demographic, clinical, and outcome data were collected for infants with GBS recovered from blood or cerebrospinal fluid culture from January 1, 2006 to July 1, 2012.
RESULTS: Totally 48 infants were identified (42 LO, 6 VLO). Infants with VLO sepsis had lower median gestational age (28.5 vs. 39 weeks gestation, P<0.001) and longer median nursery admissions (8.8 vs. 0.5 weeks, P=0.004). When gestational age was controlled for, there were no differences in clinical presentation, intensive care unit admission, length of stay, neurodevelopmental outcome, and mortality. Infants with VLO sepsis were more likely to receive vancomycin (83% vs. 33%, P=0.02) or third-generation cephalosporins (83% vs. 24%, P=0.009), and more likely to continue on those agents even after GBS was identified.
CONCLUSIONS: Infants with VLO sepsis had lower gestational ages and longer nursery stays than infants with LO sepsis. Beyond age at presentation, there were no significant differences in clinical presentations, hospital course, frequency of neurodevelopmental sequelae, and mortality in infants presenting with LO vs. VLO GBS sepsis. Infants with VLO sepsis were more likely to receive empiric broad spectrum antimicrobials and more likely to continue receiving broad therapy even following GBS identification.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464660     DOI: 10.1007/s12519-014-0450-8

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  9 in total

1.  Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.

Authors:  Barbara J Stoll; Nellie I Hansen; Pablo J Sánchez; Roger G Faix; Brenda B Poindexter; Krisa P Van Meurs; Matthew J Bizzarro; Ronald N Goldberg; Ivan D Frantz; Ellen C Hale; Seetha Shankaran; Kathleen Kennedy; Waldemar A Carlo; Kristi L Watterberg; Edward F Bell; Michele C Walsh; Kurt Schibler; Abbot R Laptook; Andi L Shane; Stephanie J Schrag; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2011-04-25       Impact factor: 7.124

2.  Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.

Authors:  Morven S Edwards; Heidi J Lane; Sharon L Hillier; Marcia A Rench; Carol J Baker
Journal:  Vaccine       Date:  2012-04-24       Impact factor: 3.641

3.  Single-dose penicillin prophylaxis against neonatal group B streptococcal infections. A controlled trial in 18,738 newborn infants.

Authors:  J D Siegel; G H McCracken; N Threlkeld; B Milvenan; C R Rosenfeld
Journal:  N Engl J Med       Date:  1980-10-02       Impact factor: 91.245

4.  Group B streptococcus late-onset disease: 2003-2010.

Authors:  Alberto Berardi; Cecilia Rossi; Licia Lugli; Roberta Creti; Maria Letizia Bacchi Reggiani; Marcello Lanari; Luigi Memo; Maria Federica Pedna; Claudia Venturelli; Enrica Perrone; Matilde Ciccia; Elisabetta Tridapalli; Marina Piepoli; Raffaella Contiero; Fabrizio Ferrari
Journal:  Pediatrics       Date:  2013-01-06       Impact factor: 7.124

5.  Long-term outcomes of group B streptococcal meningitis.

Authors:  Romina Libster; Kathryn M Edwards; Fatma Levent; Morven S Edwards; Marcia A Rench; Luis A Castagnini; Timothy Cooper; Robert C Sparks; Carol J Baker; Prachi E Shah
Journal:  Pediatrics       Date:  2012-06-11       Impact factor: 7.124

6.  Prevention of neonatal group B streptococcal disease: A combined intrapartum and neonatal protocol.

Authors:  George D Wendel; Kenneth J Leveno; Pablo J Sánchez; Gregory L Jackson; Donald D McIntire; Jane D Siegel
Journal:  Am J Obstet Gynecol       Date:  2002-04       Impact factor: 8.661

7.  Trends in perinatal group B streptococcal disease - United States, 2000-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-02-13       Impact factor: 17.586

8.  Invasive group B streptococcal disease in children beyond early infancy.

Authors:  S M Hussain; G S Luedtke; C J Baker; P M Schlievert; R J Leggiadro
Journal:  Pediatr Infect Dis J       Date:  1995-04       Impact factor: 2.129

9.  Late and ultra late onset Streptococcus B meningitis: clinical and bacteriological data over 6 years in France.

Authors:  J Guilbert; C Levy; R Cohen; C Delacourt; Sylvain Renolleau; Cyril Flamant
Journal:  Acta Paediatr       Date:  2010-01       Impact factor: 2.299

  9 in total
  3 in total

1.  Modification of the CpsA protein reveals a role in alteration of the Streptococcus agalactiae cell envelope.

Authors:  Hannah M Rowe; Brett R Hanson; Donna L Runft; Qian Lin; Steve M Firestine; Melody N Neely
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

2.  Group B Streptococcus causes severe sepsis in term neonates: 8 years experience of a major Chinese neonatal unit.

Authors:  Ying Dong; Si-Yuan Jiang; Qi Zhou; Yun Cao
Journal:  World J Pediatr       Date:  2017-05-09       Impact factor: 2.764

3.  Bacteremia in Early Infancy: Etiology and Management.

Authors:  Joseph B Cantey; Amanda C Farris; Sarah M McCormick
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.